Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 9/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648252 | 1.00 | HTR7 (0.43) | HTR7MAPTL3MBTL1HPGDRAB9A | |
| SCHEMBL26636424 | 0.95 | HTR7 (0.42) | HTR7MAPTL3MBTL1HPGDRAB9A | |
| SCHEMBL26636905 | 0.91 | HTR7 (0.44) | HTR7MAPTL3MBTL1HPGDRAB9A | |
| SCHEMBL22807537 | 0.90 | MAPT (0.39) | HTR7MAPTL3MBTL1HPGDRAB9A | |
| Bicarbonate SCHEMBL29992844 | 0.89 | SMN1; SMN2 (0.39) | HTR7MAPTL3MBTL1HPGDRAB9A | |
| SCHEMBL18728445 | 0.85 | HTR7 (0.43) | HTR7MAPTL3MBTL1HPGDRAB9A | |
| SCHEMBL29772127 | 0.85 | HTR7 (0.43) | HTR7MAPTL3MBTL1HPGDRAB9A | |
| SCHEMBL28751083 | 0.85 | CYP1A2 (0.50) | HTR7MAPTL3MBTL1HPGDRAB9A | |
| SCHEMBL30504433 | 0.84 | HTR1B (0.50) | HTR7MAPTL3MBTL1HPGDRAB9A | |
| SCHEMBL18757446 | 0.84 | HTR1B (0.50) | HTR7MAPTL3MBTL1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-11 | — | — | US | disclosed |
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4519260-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XDEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240374595-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-11-14 | — | — | US | disclosed |
| US-12083118-B2 | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-09-10 | — | — | US | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| CN-112566900-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240124417-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4332099-A1 | NOVEL BIPHENYL DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | Xi'an Xintong Pharmaceutical Research Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20240043392-A1 | NOVEL BIPHENYL DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | XI'AN XINTON PHARMACEUTCAL RESEARCH CO., LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| WO-2018044963-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018044963-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | disclosed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | disclosed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | disclosed |
| WO-2017066227-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066227-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083118-B2 | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same | HAVCR2, HMBS, BCL3 | HTR7 2190/4885MAPT 4050/4885L3MBTL1 645/4885 |
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2, BCL2L10, BCL2L1 | HTR7 2834/4885MAPT 3763/4885L3MBTL1 1268/4885 |
| US-20240374595-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, CDV3 | HTR7 2234/4885MAPT 4167/4885L3MBTL1 604/4885 |
| US-20240043392-A1 | NOVEL BIPHENYL DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | CD274, PDCD1, PDCD1LG2 | HTR7 3129/4885MAPT 3440/4885L3MBTL1 3210/4885 |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | HTR7 4476/4885MAPT 4038/4885L3MBTL1 3856/4885 |
| US-20240124417-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | HTR7 4476/4885MAPT 4038/4885L3MBTL1 3856/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HTR7 3678/4885MAPT 4057/4885L3MBTL1 1066/4885 |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | HTR7 4476/4885MAPT 4038/4885L3MBTL1 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.